Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Eli Lilly (NY:LLY)

1,126.88 +19.80 (+1.79%)
Streaming Delayed Price Updated: 9:45 AM EDT, Jun 24, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Eli Lilly

< Previous 1 2
...
6 7 8 9 10 11 12 13 14
...
99 100 Next >
News headline image
Is This Tech Giant the Next Potential Winner in the GLP-1 Weight Loss Boom? ↗
The weight loss drug market may reach almost $100 billion in a few years. 
Via The Motley Fool
News headline image
Why Eli Lilly Stock Flopped on Friday ↗
High hopes for a freshly approved drug might not be realized, if early data is any indication. 
Via The Motley Fool
News headline image
Why Eli Lilly (LLY) Shares Are Trading Lower Today
What Happened? Shares of global pharmaceutical company Eli Lilly (NYSE:LLY) fell 3.6% in the afternoon session after disappointing weekly prescription number... 
Via StockStory
Topics Artificial Intelligence
Uncover the latest developments among S&P500 stocks in today's session. ↗
Via Chartmill
News headline image
Deal Dispatch: QXO Nabs TopBuild For $17 Million, Voya Financial Urged To Evaluate Strategic Options, Pat McGrath Exits Chapter 11 ↗
Major M&A deals this week include Eli Lilly buys Kelonia for $7 billion, Honeywell sells PSS to Brady Corp., KSL buys Invited Clubs. 
Via Benzinga
These S&P500 stocks are gapping in today's session ↗
Via Chartmill
News headline image
Expert Matchmaker in Indianapolis Report by CX Research Institute
Via AB Newswire
Topics Economy
News headline image
Battle Of The Weight-Loss Pills Continues With A Shocking Twist ↗
Eli Lilly stock skidded early Friday as Novo Nordisk's oral Wegovy continued to outpace Lilly's new obesity pill, Foundayo. 
Via Investor's Business Daily
News headline image
This Vanguard Index Fund Could Turn $500 Per Month Into a $1.4 Million Portfolio as the AI Boom Unfolds ↗
Young adults with median earnings can build sizable portfolios by retirement by regularly purchasing shares of the Vanguard S&P 500 Growth ETF. 
Via The Motley Fool
Topics Artificial Intelligence ETFs Economy
News headline image
Q4 Earnings Roundup: Merck (NYSE:MRK) And The Rest Of The Branded Pharmaceuticals Segment
Let’s dig into the relative performance of Merck (NYSE:MRK) and its peers as we unravel the now-completed Q4 branded pharmaceuticals earnings season. Looking... 
Via StockStory
Topics Artificial Intelligence Intellectual Property
News headline image
Why Vista Just Opened a $3 Million Position in Federated Hermes ↗
Federated Hermes delivers asset management solutions across equity, fixed income, and money market funds to a diverse client base. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Amazon Aims to Take Over the GLP-1 Market Next. Will That Move the Needle for AMZN Stock?
Amazon is expanding into integrated weight-loss care with a scalable healthcare model. Can this expansion meaningfully drive AMZN stock upside? 
Via Barchart.com
Topics Artificial Intelligence
News headline image
Hims & Hers Jumps On Its New Eli Lilly-Tied Approach To Obesity ↗
Hims & Hers Health can now connect its customers with self-pay prices for Eli Lilly's weight-loss drugs. 
Via Investor's Business Daily
News headline image
Is Novo Nordisk's 72% Crash a Generational Buying Opportunity or a Value Trap? ↗
Novo Nordisk stock has been stuck in a downward spiral for quite some time. 
Via The Motley Fool
News headline image
The Longevity Trade Is No Longer a Buzzword — It's a $120 Billion Market, and the FDA Just Cleared the First Cellular Rejuvenation Trial
From stem cell therapies for frailty to α-Klotho protein programs and GLP-1 drug classes now labeled "longevity therapeutics," the science and the capital have finally met 
From Equity Insider
Via GlobeNewswire
News headline image
Forget Ozempic: This High‑Flying Device Maker Can Thrive No Matter Which Weight Loss Drug Wins ↗
Drugmakers won't be the only ones cashing in on the rising popularity of weight loss medicines. 
Via The Motley Fool
News headline image
3 Healthcare Stocks With the Most Durable Competitive Moats ↗
These companies offer a clear path to sustained earnings growth. 
Via The Motley Fool
Topics Intellectual Property
News headline image
Winners And Losers Of Q4: Elanco (NYSE:ELAN) Vs The Rest Of The Pharmaceuticals Stocks
Wrapping up Q4 earnings, we look at the numbers and key takeaways for the pharmaceuticals stocks, including Elanco (NYSE:ELAN) and its peers. The pharmaceuti... 
Via StockStory
Topics Artificial Intelligence Intellectual Property
News headline image
Is Eli Lilly Stock Actually ... Cheap? The Surprising Math Behind Its 2026 Valuation. ↗
Eli Lilly stock trades for more than $900 per share, which may appear expensive upon first glance. 
Via The Motley Fool
News headline image
Why Merck (MRK) Shares Are Trading Lower Today
What Happened? Shares of global pharmaceutical company Merck (NYSE:MRK) fell 3.8% in the afternoon session after the company, along with its partner Eisai, a... 
Via StockStory
Topics Government Intellectual Property
News headline image
Eli Lilly and Novo Nordisk's Newest Rival In Weight Loss? Amazon. ↗
Shares of Eli Lilly, Novo Nordisk and Viking Therapeutics fell Tuesday after Amazon announced it would sell weight-loss drugs. 
Via Investor's Business Daily
News headline image
Why Did Eli Lilly Stock Drop Today? ↗
Can Eli Lilly cure cancer? Maybe -- with a little help. 
Via The Motley Fool
Which S&P500 stocks are gapping on Tuesday? ↗
Via Chartmill
News headline image
A Monthly Weight Loss Shot? Why Pfizer Could Topple Lilly's and Novo's GLP-1 Duopoly ↗
There might be room for two titans in the obesity business, but a third player might have a uniquely marketable option. 
Via The Motley Fool
After Fifteen Years, Tim Cook Steps Down, Wall Street Steps Back, Oil Steps Up ↗
Via Chartmill
News headline image
Why Legend Biotech Stock Crushed the Market on Monday ↗
Two analysts weighed in positively about the company's future. 
Via The Motley Fool
News headline image
3 Giant Dividend Stocks Raising Payouts With Yields Up to 4% ↗
Johnson & Johnson, Albertsons, and Procter & Gamble have each raised their dividends, lifting yields to between 2.3% and 4% despite mixed performance in 2025. 
Via MarketBeat
News headline image
Eli Lilly Goes Atomic—But This Isn't About AI Servers ↗
Eli Lilly's nuclear move signals a shift beyond AI, as industrial giants like Nucor and Dow turn to reactors for reliable, 24/7 power. 
Via Benzinga
Topics Artificial Intelligence Stocks
News headline image
Eli Lilly Snags $7 Billion Cancer Deal To Rival Gilead, J&J, Others ↗
Eli Lilly said Monday it will spend up to $7 billion to buy privately held Kelonia Therapeutics for its suite of cancer drugs. 
Via Investor's Business Daily
News headline image
Will Eli Lilly's New GLP-1 Pill Get the Stock Get Back to a $1 Trillion Valuation? ↗
Regulators approved the company's GLP-1 weight loss pill, Foundayo, at the beginning of April. 
Via The Motley Fool
< Previous 1 2
...
6 7 8 9 10 11 12 13 14
...
99 100 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.